European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab

PARIS (Reuters) – The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Source: Reuters Medical News